Cargando…

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

BACKGROUND: AGI-101H is an allogeneic gene modified whole cell therapeutic melanoma vaccine, evaluated in over 400 melanoma patients in the adjuvant and therapeutic settings. We present updated long-term survival results from two single-arm, phase II adjuvant trials (Trial 3 and Trial 5) with the fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mackiewicz, Jacek, Burzykowski, Tomasz, Iżycki, Dariusz, Mackiewicz, Andrzej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Clinical Trials Monitor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264600/ https://www.ncbi.nlm.nih.gov/pubmed/30486884 http://dx.doi.org/10.1186/s40425-018-0456-1

Ejemplares similares

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma
por: Jacek, Mackiewicz, et al.
Publicado: (2015)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Recent advances in melanoma treatment – American Society of Clinical Oncology (ASCO) 2012 perspective
por: Mackiewicz, Jacek, et al.
Publicado: (2012)

What is new in the treatment of advanced melanoma? State of the art
por: Mackiewicz, Jacek
Publicado: (2012)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
por: Jiang, Haiping, et al.
Publicado: (2022)

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
por: Przybyla, Anna, et al.
Publicado: (2021)

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
por: Grigg, Claud, et al.
Publicado: (2016)

‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies?
por: Pettinger, Claire, et al.
Publicado: (2022)

Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis
por: Wiater, Katarzyna, et al.
Publicado: (2013)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6
por: Czerwinska, Patrycja, et al.
Publicado: (2020)

Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients
por: Kamińska, Paula, et al.
Publicado: (2023)

Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2017)

Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma
por: Middleton, Gary
Publicado: (2020)

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients
por: Kwiatkowska-Borowczyk, Eliza, et al.
Publicado: (2018)

Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine
por: Page, David B., et al.
Publicado: (2016)

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
por: Rehman, Hasan, et al.
Publicado: (2016)

Current clinical trials testing the combination of immunotherapy with radiotherapy
por: Kang, Josephine, et al.
Publicado: (2016)

Design considerations for early-phase clinical trials of immune-oncology agents
por: Wages, Nolan A., et al.
Publicado: (2018)

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
por: Redman, Jason M., et al.
Publicado: (2018)

Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial
por: Zamarin, Dmitriy, et al.
Publicado: (2020)

GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
por: DeNardo, David G, et al.
Publicado: (2021)

Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
por: Anders, Carey K, et al.
Publicado: (2022)

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
por: Pietrzak, Bernadeta, et al.
Publicado: (2022)

Analysis of sequence variants in the 3'UTR of CDKN2A gene in melanoma patients
por: Przybyła, Anna, et al.
Publicado: (2015)

Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events: results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) study
por: Sack, Stefan, et al.
Publicado: (2011)

Hybrid approaches to clinical trial monitoring: Practical alternatives to 100% source data verification
por: De, Sourabh
Publicado: (2011)

A day in the life of a monitor!
por: Shah, Kunal
Publicado: (2012)

Biocrust morphogroups provide an effective and rapid assessment tool for drylands
por: Read, Cassia F., et al.
Publicado: (2014)

FORUM: Ecological networks: the missing links in biomonitoring science
por: Gray, Clare, et al.
Publicado: (2014)

Tree‐centric mapping of forest carbon density from airborne laser scanning and hyperspectral data
por: Dalponte, Michele, et al.
Publicado: (2016)

LATS1 Is a Mediator of Melanogenesis in Response to Oxidative Stress and Regulator of Melanoma Growth
por: Kazimierczak, Urszula, et al.
Publicado: (2021)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Morphine promotes migration and lung metastasis of mouse melanoma cells
por: Vaseghi, Golnaz, et al.
Publicado: (2022)

Melanoma Stem Cell-Like Phenotype and Significant Suppression of Immune Response within a Tumor Are Regulated by TRIM28 Protein
por: Czerwinska, Patrycja, et al.
Publicado: (2020)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
por: Tomela, Katarzyna, et al.
Publicado: (2020)

Interference of COVID-19 Vaccination With PET/CT Leads to Unnecessary Additional Imaging in a Patient With Metastatic Cutaneous Melanoma—Case Report
por: Czepczyński, Rafał, et al.
Publicado: (2021)

A designer hyper interleukin 11 (H11) is a biologically active cytokine
por: Dams-Kozlowska, Hanna, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4qj3622444ehpq2fju7dsokou9